Evidence map›Paper›PMID 31416077›Full record

ArticleAmerican journal of nephrology2019

Knockout of Sphingosine Kinase 1 Attenuates Renal Fibrosis in Unilateral Ureteral Obstruction Model.

Xiwen Zhang, Weili Wang, Xin-Ying Ji, Joseph K Ritter, Ningjun Li

Open access · bronzeAbstract read
In one paragraph

Article in American journal of nephrology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Sphingolipid Metabolism in the Pathogenesis of Hashimoto's Thyroiditis.International journal of molecular sciences · 2025
    Review
  3. Article
  4. Sphingolipid signaling in kidney diseases.American journal of physiology. Renal physiology · 2025
    Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Loss of sphingosine kinase 2 protects against cisplatin-induced kidney injury.American journal of physiology. Renal physiology · 2022
    Article
  11. Article
  12. Article
  13. Review
  14. Nephrotoxicity in cancer treatment: An update.Advances in cancer research · 2022
    Article
  15. Article
  16. Loss ofHypertension (Dallas, Tex. : 1979) · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Xiwen ZhangDepartment of Pharmacology and Toxicology, Virginia Commonwealth University School of Medicine, Richmond, Virginia, USA.
Weili WangDepartment of Pharmacology and Toxicology, Virginia Commonwealth University School of Medicine, Richmond, Virginia, USA.
Xin-Ying JiHenan International Joint Laboratory for Nuclear Protein Regulation, School of Basic Medical Sciences, Henan University College of Medicine, Kaifeng, China.
Joseph K RitterDepartment of Pharmacology and Toxicology, Virginia Commonwealth University School of Medicine, Richmond, Virginia, USA.
Ningjun LiDepartment of Pharmacology and Toxicology, Virginia Commonwealth University School of Medicine, Richmond, Virginia, USA, nli@vcu.edu.
Virginia Commonwealth University · USHenan University · CN

Funding

Renal sphingosine-1-phosphate receptor 1 in salt-sensitive hypertensionR01HL145163 · NHLBI · VIRGINIA COMMONWEALTH UNIVERSITY · PI LI, NINGJUN · 2019 to 2022
$1.6M
Renomedullary metabolism of anandamide and blood pressure regulationR01DK102539 · NIDDK · VIRGINIA COMMONWEALTH UNIVERSITY · PI LI, PINLAN, RITTER, JOSEPH K. · 2016 to 2019
$1.4M
Molecular mechanism of hypertension-induced renal injury: the role of HIF-1alphaR01DK107991 · NIDDK · VIRGINIA COMMONWEALTH UNIVERSITY · PI LI, NINGJUN · 2017 to 2019
$698k
Renomedullary metabolism of anandamide and blood pressure regulationR56DK102539 · NIDDK · VIRGINIA COMMONWEALTH UNIVERSITY · PI LI, PINLAN, RITTER, JOSEPH K. · 2014 to 2014
$92k
NHLBI NIH HHS R01 HL145163NIDDK NIH HHS R01 DK102539NIDDK NIH HHS R01 DK107991NIDDK NIH HHS R56 DK102539
6 · The paper itself

Abstract

backgroundSphingosine-1-phosphate (S1P) is a bioactive sphingolipid metabolite involved in various diseases. S1P also plays significant roles in the differentiation of fibroblasts into myofibroblasts, being implicated in fibrotic diseases. S1P is produced by the phosphorylation of sphingosine catalyzed by sphingosine kinases (SphK1 and SphK2). It remains unclear if the activation of endogenous SphK1 contributes to fibrogenesis in kidneys. The present study determined the effect of SphK1 gene knockout (KO) on fibrotic markers in kidneys.

methodsThe renal fibrosis was produced using the unilateral ureteral obstruction (UUO) model in wild-type (WT) and SphK1 gene KO mice. Renal mRNA levels of SphK1 and S1P receptors (S1PR) were measured by real-time RT-PCR. Fibrotic and immune cell markers in kidneys were measured by Western blot analysis and immunostaining, respectively. Renal morphological damage was examined by Periodic-Acid Schiff staining.

resultsThe mRNA levels of SphK1 and S1PRs were dramatically increased in renal tissues of WT-UUO mice, whereas the increase in renal SphK1 mRNA was blocked in KO-UUO mice. Interestingly, the increased levels of fibrotic markers, collagen and α-smooth muscle actin, in kidneys were significantly attenuated in KO-UUO versus WT-UUO mice. Meanwhile, kidney damage indices were remarkably attenuated in KO-UUO mice compared with WT-UUO mice. However, increased numbers of CD43+ and CD48+ cells, markers for T cell and macrophage, respectively, showed no significant difference between -WT-UUO and KO-UUO kidneys.

conclusionThe activation of the SphK1-S1P pathway may contribute to tubulointerstitial fibrosis in UUO kidneys by affecting fibrotic signaling within renal cells independent of immune modulation.

Indexed as

AnimalsDisease Models, AnimalFibroblastsFibrosisGene DeletionImmune SystemInflammationKidneyMaleMiceMice, Inbred C57BLMice, KnockoutPhosphorylationPhosphotransferases (Alcohol Group Acceptor)Renal Insufficiency, ChronicSphingosine KinasePhosphotransferases (Alcohol Group Acceptor)Sphingosine Kinasesphingosine kinase 2, mouseSphk1 protein, mouseCollagenSphingosine-1-phosphateα-Smooth muscle actin

Identifiers

PMID31416077
PMCPMC6754627
OpenAlexW2967693628

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.